tailieunhanh - Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN